Vanda Pharmaceuticals (VNDA) Aandelenoverzicht
Vanda Pharmaceuticals Inc. is een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling en commercialisering van therapieën voor grote onbeantwoorde medische behoeften wereldwijd. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
VNDA Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vanda Pharmaceuticals Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$6.18 |
| 52 Week Hoogtepunt | US$9.94 |
| 52 Week Laag | US$4.14 |
| Bèta | 0.65 |
| 1 maand verandering | -11.59% |
| 3 maanden verandering | 1.31% |
| 1 Jaar Verandering | 43.06% |
| 3 jaar verandering | 1.15% |
| 5 jaar verandering | -65.72% |
| Verandering sinds IPO | -36.16% |
Recent nieuws en updates
Narratiefupdate • May 17
VNDA: Psychiatry Franchise And New Launches Will Drive Earnings Repricing
Analysts have adjusted the fair value estimate for Vanda Pharmaceuticals to $14.90 from $12.67, reflecting updated expectations for profitability, P/E assumptions, and the potential contribution from BYSANTI and other near-commercial assets highlighted in recent research. Analyst Commentary Recent Street research on Vanda Pharmaceuticals presents a mixed picture, with some analysts emphasizing upside from newly approved and near-commercial assets, while others are trimming targets as expectations and assumptions are recalibrated.Seeking Alpha • May 13
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
Summary Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price appreciation as of Tuesday's data. Earnings and cash flow trends remain weak, with persistent operating losses, high R&D costs, and no profitability expected until at least 2030. Technical analysis signals a neutral trend, but recent drug launches and upgraded revenue guidance provide a potential growth catalyst. The risk of cash burn was highlighted as well, with about 1.6 years of cash runway expected at current burn rates unless it improves soon. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • May 17
VNDA: Psychiatry Franchise And New Launches Will Drive Earnings Repricing
Analysts have adjusted the fair value estimate for Vanda Pharmaceuticals to $14.90 from $12.67, reflecting updated expectations for profitability, P/E assumptions, and the potential contribution from BYSANTI and other near-commercial assets highlighted in recent research. Analyst Commentary Recent Street research on Vanda Pharmaceuticals presents a mixed picture, with some analysts emphasizing upside from newly approved and near-commercial assets, while others are trimming targets as expectations and assumptions are recalibrated.Seeking Alpha • May 13
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
Summary Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price appreciation as of Tuesday's data. Earnings and cash flow trends remain weak, with persistent operating losses, high R&D costs, and no profitability expected until at least 2030. Technical analysis signals a neutral trend, but recent drug launches and upgraded revenue guidance provide a potential growth catalyst. The risk of cash burn was highlighted as well, with about 1.6 years of cash runway expected at current burn rates unless it improves soon. Read the full article on Seeking Alpha
Narratiefupdate • Apr 28
VNDA: Psychiatry Franchise And Nereus Data Will Shape Balanced Future Prospects
Analysts have raised their average price target on Vanda Pharmaceuticals by $3, from $14 to $17, citing updated revenue models after BYSANTI's approval, expectations for growth in the psychiatry franchise, and potential upside from additional commercial and near-commercial assets. Analyst Commentary Recent research has highlighted a more constructive tone around Vanda Pharmaceuticals, with multiple firms publishing views that anchor on BYSANTI, the broader psychiatry franchise, and the company’s commercial portfolio.Narratiefupdate • Apr 14
VNDA: Psychiatry Franchise And Nereus Opportunity Will Shape Balanced Future Upside
Analysts have raised their average price target for Vanda Pharmaceuticals to reflect updated expectations around the recently approved BYSANTI, ongoing prescriptions for Fanapt, and potential upside from Nereus in GLP-1 related vomiting, with current targets from recent research ranging from $17 to $24. Analyst Commentary Recent research has generally been constructive on Vanda Pharmaceuticals, with several firms assigning Buy ratings alongside price targets in the mid to high teens and low twenties.
Narratiefupdate • Mar 31
VNDA: Psychiatry Franchise And GLP 1 Vomiting Opportunity Will Shape 2026 Outlook
Analysts have raised their fair value estimate for Vanda Pharmaceuticals to $24 from $22, reflecting updated models that incorporate the FDA approval of Bysanti, higher expectations for the psychiatry franchise, and emerging opportunities such as Nereus in GLP-1 related vomiting. Analyst Commentary Bullish analysts are leaning into Vanda's updated story around Bysanti, Fanapt, and newer assets, with several raising fair value assumptions and highlighting a broader psychiatry and gastrointestinal opportunity set.Narratiefupdate • Mar 16
VNDA: Psychiatry Reliance Will Limit Upside Despite Recent Drug Approvals
Analysts have raised their average price targets for Vanda Pharmaceuticals into the mid to high teens in dollar terms, citing the recent FDA approval of Bysanti, updated revenue models for the psychiatry franchise, and potential upside from the Nereus program as key reasons for the change. Analyst Commentary Recent Street research around Vanda Pharmaceuticals has centered on the implications of Bysanti's FDA approval, the outlook for the psychiatry franchise, and the potential contribution of pipeline assets such as Nereus and tasimelteon.Narratiefupdate • Mar 02
VNDA: Psychiatry Concentration Risk Will Drive A Cautious Forward Outlook
Analysts have lifted their average price target for Vanda Pharmaceuticals to a higher range of $17 to $24, citing updated revenue models that now include expected BYSANTI contributions and revised assumptions for its psychiatry franchise. Analyst Commentary Recent research has centered on the impact of BYSANTI and the broader psychiatry franchise on Vanda Pharmaceuticals, with updated revenue models now reflecting expected BYSANTI contributions and revised assumptions around prescription trends.Narratiefupdate • Feb 16
VNDA: Jet Lag Setback Will Keep Focus On 2026 Earnings Outlook
Analysts kept their $22 price target for Vanda Pharmaceuticals unchanged, citing recent FDA feedback on tasimelteon for jet lag as a limited setback that was already excluded from their valuation assumptions. Analyst Commentary Bullish analysts frame the recent FDA feedback on tasimelteon for jet lag as a contained issue.Narratiefupdate • Feb 02
VNDA: Jet Lag Setback Will Keep Focus On Imsidolimab BLA Milestone
Analysts have lifted their fair value estimate for Vanda Pharmaceuticals to $22 from $20, citing Street research that views the recent FDA decision on tasimelteon for jet lag as a limited setback that was not factored into prior valuation work. Analyst Commentary Bullish analysts frame the FDA decision on tasimelteon for jet lag as a limited setback rather than a thesis changer for Vanda Pharmaceuticals.Narratiefupdate • Jan 19
VNDA: Imsidolimab Filing And Motion Sickness Approval Will Shape Balanced Outlook
Analysts have kept their fair value estimate for Vanda Pharmaceuticals steady at US$7.50, while modestly updating assumptions for the discount rate, revenue growth, profit margin, and future P/E after viewing the recent tasimelteon sNDA setback as a limited issue that was not central to their prior price target work. Analyst Commentary Street research commentary around Vanda Pharmaceuticals has framed the recent tasimelteon update as a limited issue for the equity story, with some firms explicitly stating that their valuation work did not depend on jet lag revenues for HETLIOZ.Narratiefupdate • Jan 04
VNDA: Imsidolimab Milestones And Motion Sickness Launch Will Drive Balanced Outlook
Analysts have modestly raised their fair value estimate for Vanda Pharmaceuticals to approximately $7.50 from about $5.00 per share, citing improving milestone visibility tied to the anticipated imsidolimab BLA submission and a reassessment of long term earnings potential, even as revenue growth assumptions have become more tempered. Analyst Commentary Bearish analysts acknowledge that the clearer path toward an imsidolimab BLA filing has improved Vanda's long term earnings visibility, but they remain wary that the ultimate revenue contribution could fall short of current expectations.
Nieuw narratief • Apr 24
New Indications And Pipeline Advances Will Strengthen Position
Expansion of Fanapt's sales and marketing efforts is expected to drive significant revenue growth through increased brand awareness and prescriber engagement.Seeking Alpha • Sep 05
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Summary Fanapt, approved for bipolar I disorder, faces significant competition from generics like Abilify, making it unlikely to drive substantial revenue growth. Ponvory, acquired from Janssen, faces similar competitive pressures, with generic versions of similar drugs dominating the multiple sclerosis market. Despite failing its primary endpoint in gastroparesis, Vanda is still pushing for regulatory approval for tradipitant, facing regulatory hurdles. Despite receiving two acquisition offers with a premium, Vanda rejected them, raising concerns about their cash management and future stock performance. Vanda's stock remains a hold due to cash strength, but limited product pipeline differentiation makes long-term growth prospects challenging. Read the full article on Seeking AlphaSeeking Alpha • Aug 08
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Summary Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operations. Vanda has disgruntled shareholders who may find creative ways to maximize shareholder value, despite a recent AGM failing to oust the unpopular Board of Directors and an existing poison pill. Retail shareholders can buy Vanda for less than the company's cash value, getting the potential benefit from the actions of activist shareholders for free. Read the full article on Seeking AlphaSeeking Alpha • Jun 18
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Summary Vanda Pharmaceuticals’ portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA’s upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA’s undervaluation and strategic value. VNDA trades below its cash value, with significant cash reserves and no debt, suggesting financial stability and growth potential. VNDA's diversified late-stage IP and substantial TAM make it a compelling investment despite the biotech and M&A risks. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Summary Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not significantly contribute to Vanda's bottom line as there are already several drugs approved for this indication. Despite a strong balance sheet, Vanda's future is heavily reliant on expanding existing drugs indications and new drug successes. Maintain "Hold" recommendation: Fanapt's bipolar indication is unlikely to significantly impact revenue; the company faces moderate-to-high risk. Read the full article on Seeking AlphaAnalyseartikel • Feb 15
Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) stock, leading do a rise in the share price...Seeking Alpha • Feb 13
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Summary Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share). Multiple FDA approvals, if forthcoming, in 2024 could prove to be material catalysts, perhaps highlighting that the company has operational assets beyond its cash. The market's current valuation of VNDA appears too pessimistic and a range of $5-10/share may be more reasonable, even assuming imperfect capital allocation. There could be further upside if drug approvals and operational performance go well in 2024. If things trend poorly, a valuation below $4/share is possible if operational performance is weak in 2024 and FDA approvals are not forthcoming. Read the full article on Seeking AlphaAnalyseartikel • Feb 10
Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong...Analyseartikel • Nov 11
News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
One thing we could say about the covering analyst on Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ) - they aren't...Rendement voor aandeelhouders
| VNDA | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -3.9% | -3.0% | -0.3% |
| 1Y | 43.1% | 32.9% | 26.7% |
Rendement versus industrie: VNDA overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 32.9 % opleverde.
Rendement versus markt: VNDA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 26.7 %.
Prijsvolatiliteit
| VNDA volatility | |
|---|---|
| VNDA Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van VNDA is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 15% ) van VNDA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2002 | 533 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., een biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van therapieën om te voorzien in grote onbeantwoorde medische behoeften wereldwijd. De commerciële portefeuille van het bedrijf omvat Fanapt voor de acute behandeling van manische of gemengde episoden die geassocieerd worden met bipolaire stoornis I en de behandeling van schizofrenie; HETLIOZ voor de behandeling van slaapstoornissen die geen 24 uur per dag duren en nachtelijke slaapstoornissen; PONVORY voor de behandeling van recidiverende vormen van multiple sclerose; en NEREUSTM voor het voorkomen van braken veroorzaakt door beweging. Het ontwikkelt ook Fanapt (iloperidone), een langwerkende injecteerbare (LAI) formulering voor de behandeling van schizofrenie en hypertensie; BysantiTM (milsaperidone), voor de acute behandeling van manische of gemengde episoden geassocieerd met bipolaire stoornis I, en voor de behandeling van schizofrenie en depressieve stoornis; HETLIOZ (tasimelteon) voor de behandeling van jetlagstoornissen, slapeloosheid, pediatrische slapeloosheid, stoornissen in de vertraagde slaapfase en pediatrische Non-24; PONVORY (ponesimod) voor de behandeling van psoriasis en colitis ulcerosa; en NEREUSTM (tradipitant) voor de preventie van braken veroorzaakt door GLP-1-receptoragonisten, alsook voor de behandeling van gastroparese en atopische dermatitis.
Vanda Pharmaceuticals Inc. Samenvatting
| VNDA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$360.21m |
| Inkomsten(TTM) | -US$239.55m |
| Inkomsten(TTM) | US$217.78m |
1.7x
P/S-verhouding-1.6x
Koers/WinstverhoudingIs VNDA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| VNDA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$217.78m |
| Kosten van inkomsten | US$12.68m |
| Brutowinst | US$205.10m |
| Overige uitgaven | US$444.65m |
| Inkomsten | -US$239.55m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.98 |
| Brutomarge | 94.18% |
| Nettowinstmarge | -109.99% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde VNDA op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/20 15:59 |
| Aandelenkoers aan het einde van de dag | 2026/05/20 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Vanda Pharmaceuticals Inc. wordt gevolgd door 18 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |